Skip to content
HowShorted

Apellis Pharmaceuticals, Inc. short interest in 2022

In 2022, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 7.15% of shares outstanding on 14 Jan 2022 to 8.30% on 30 Dec 2022, a change of +1.15 percentage points. The year's high was 9.39% on 15 Nov 2022 and its low 7.15% on 14 Jan 2022, averaging 8.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.90 days on 15 Jun 2022. Full history: Apellis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Apellis Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
7.15% (14 Jan 2022)
End of year
8.30% (30 Dec 2022)
Change
+1.15 pp
High
9.39% (15 Nov 2022)
Low
7.15% (14 Jan 2022)
Average
8.41%
Highest days to cover
11.90 (15 Jun 2022)
SEC filings marked
5

Every report in 2022

Apellis Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.15%7.67results (8-K)
31 Jan 20228.36%6.16
15 Feb 20227.98%9.15
28 Feb 20227.87%10.5510-K filed
15 Mar 20227.32%6.29
31 Mar 20228.35%3.81
14 Apr 20228.99%6.87
29 Apr 20228.28%9.74
13 May 20228.59%7.1310-Q filed
31 May 20228.42%9.24
15 Jun 20228.59%11.90
30 Jun 20229.20%9.39
15 Jul 20228.79%11.13
29 Jul 20229.23%5.61
15 Aug 20227.27%7.2410-Q filed
31 Aug 20227.62%6.45
15 Sep 20228.28%5.23
30 Sep 20228.94%7.46
14 Oct 20227.99%5.42
31 Oct 20228.86%11.04
15 Nov 20229.39%4.4810-Q filed
30 Nov 20228.92%6.15
15 Dec 20229.09%9.65
30 Dec 20228.30%10.68

See also: Apellis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.